PITTSTON, ME--(Marketwire - Feb 25, 2013) - YaFarm Technologies, Inc. ( PINKSHEETS : YFRM ) (YaFarm, or the Company) announced todaythatthe Integrative Stem Cell Institute (ISCI), apremier provider of point-of-care, stem cell-based therapies, has initiatedits first clinical study in Degenerative Neuromuscular Diseases (DNMD).

The clinical studies will be conducted at the ISCI facility in the Hospital Galenia in Cancun, Mexico and will consist of an integrative approach that will combine autologous, adult progenitor (stem) cells with physical therapy, nutrition and other complementary treatments to multiple sclerosis (MS),Alzheimer'sand Parkinson's disease.Patients will spend up to three weeks in Cancun for the therapies. The patient's own cells will be processed in the ISCI's state-of-the-art laboratory with a class 10,000, ISO 7 clean room.As part of the study protocol all patients will have to meet a strict set of inclusion and exclusion criteria and be evaluated by a 3rd party physician prior to treatment who will also serve to provide long-term and independent collection of outcome data, and the reporting of any adverse event or complication stemming from the treatment.

"Today there are literally hundreds of thousands of people living with DNMD," says David Audley, CEO of the ISCI. "Estimates from the National Institutes of Health provide a grim reminder to what many already know: these diseases touch many people." The National Institutes for Neurological Disorders and Stroke (NINDS) estimates that there are currently 250,000 people in the US alone with MS(1), while the University of Kansas Institute for Neurological Discoveries believes thatParkinson's disease affects nearly 1.5 million(2) and the National Institutes forAging estimates that over 5 million Americans may suffer fromAlzheimer's.(3) "And while conventional medicine may provide relief for many," continues Mr Audley, "Thousands of others find themselves suffering with limited or no options for treatment. It is for these patients that we have initiated these studies."

About The Integrative Stem Cell Institute (ISCI)The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at http://www.iscelli.com

SAFE HARBOR STATEMENT

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.

(1) NINDS: http://www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm

(2) Univ of Kansas: http://www.indkc.org/neuromuscular_and_movement.html

(3) NIA: http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet

See the original post here:
YaFarm Technologies Announces ISCI Clinical Study